Roivant Sciences Ltd. Common Shares Stock Prediction
AI-powered sentiment analysis and prediction trends for ROIV, updated each market day.
ROIV AI Sentiment
AI sees no strong directional signal for Roivant Sciences Ltd. Common Shares stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Roivant Sciences Ltd. Common Shares
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Sector
Exchange
Market Cap
$20,383,168,381
Cap Tier
Employees
750
Headquarters
LONDON
Listed Since
Oct. 1, 2021
Website
ROIV Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ROIV Volatility
Roivant Sciences Ltd. Common Shares has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
